Madrigal pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, the need for liver transplant and premature mortality.

A madrigal is a form of Renaissance choral music known for beautiful harmonies. Madrigal’s work focuses on restoring balance and harmony to the liver, an organ that performs over 500 different vital functions in the human body.

What began as a small team of researchers in Conshohocken, Pennsylvania, U.S., is now a fully integrated biopharmaceutical company with more than 500 employees in the United States and Europe. United by a single purpose—to lead the fight against MASH—Madrigal has built the leading clinical development program in this field.

Madrigal aims to support health systems and patients living with MASH through our innovations before the devastating complications of advanced liver disease occur. By partnering with healthcare providers and the patient community, we aim to educate, empower and advocate for those impacted by MASH.

Please join our Madrigal sponsored symposium at 13:00 in Theatre A, Wednesday 22nd October, that will explore MASH in people living with diabetes. We will also be at Stand B30 in the exhibition area, so please visit us to learn more.

This newsletter article & related email content are prepared and sponsored by Madrigal Pharmaceuticals.
MED-UK--2500002   
Date of reparation: October 2025